Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03723499 | Endoscopic Treatment of Bronchial Carcinoid Tumors | completed | — | 70 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01469572 | Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT01435122 | A Study of Axitinib in Advanced Carcinoid Tumors | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT00019474 | Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | completed | Phase 2 | 60 | Montefiore Medical CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT01504399 | Rhinological Outcomes in Endonasal Pituitary Surgery | completed | — | 235 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT03592940 | The Management of Neuroendocrine Tumours: A Nutritional Viewpoint.(NetNutr) | completed | — | 100 | Federico II UniversityOTHER | 1 | Jul 19, 2018 | clinicaltrials |
| NCT02279602 | Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study | completed | Phase 2 | 7 | Mateon TherapeuticsINDUSTRY | 1 | Apr 17, 2018 | clinicaltrials |
| NCT02084134 | Peri-Operative Steroid Management in Patients(Steroid) | completed | N/A | 43 | Washington University School of MedicineOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT01024387 | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 8, 2018 | clinicaltrials |
| NCT02574793 | Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects | completed | — | 60 | Huashan HospitalOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02299089 | Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) | completed | Phase 2 | 12 | Camurus ABINDUSTRY | 4 | Dec 15, 2017 | clinicaltrials |
| NCT02132468 | A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers(GI-NETorPNET) | completed | Phase 2 | 18 | Mateon TherapeuticsINDUSTRY | 1 | Dec 5, 2017 | clinicaltrials |
| NCT03271918 | Cabergoline in Nonfunctioning Pituitary Adenomas | completed | Phase 3 | 140 | University of Sao Paulo General HospitalOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT00001191 | The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid | completed | Phase 2 | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT03183271 | Proton Boost for Locally Advanced HEAD AND NECK TUMORS | completed | N/A | 20 | CNAO National Center of Oncological HadrontherapyOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00654160 | Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 7 | Mayo ClinicOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT00815620 | Best Therapy for Patients With Neuroendocrine Tumors(BESTTHERAPYNET) | completed | — | 150 | Zentralklinik Bad BerkaOTHER | 1 | Mar 21, 2017 | clinicaltrials |
| NCT02685553 | Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project | completed | Phase 1 | 10 | Universita di VeronaOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT00050349 | EPO906 in Carcinoid and Other Neuroendocrine Tumors | completed | Phase 2 | 33 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 1, 2017 | clinicaltrials |
| NCT00398320 | Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors | completed | Phase 2 | 40 | Pamela L. KunzOTHER | 1 | Mar 1, 2017 | clinicaltrials |
| NCT00093782 | Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00965250 | Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2016 | clinicaltrials |
| NCT00804336 | Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | completed | Phase 1 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 19, 2016 | clinicaltrials |
| NCT01371643 | Surgical Debulking of Pituitary Adenomas | completed | Phase 4 | 41 | NYU Langone HealthOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT01620138 | Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | completed | Phase 2 / Phase 3 | 21 | Universidade Federal do Rio de JaneiroOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT00580320 | Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma | completed | Phase 1 | 17 | Virginia Commonwealth UniversityOTHER | 1 | Aug 18, 2016 | clinicaltrials |
| NCT00869050 | Capecitabine and Temozolomide for Neuroendocrine Cancers | completed | Phase 2 | 41 | Columbia UniversityOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT01099228 | Combination Targeted Radiotherapy in Neuroendocrine Tumors | completed | N/A | 2 | David BushnellOTHER | 1 | Jul 21, 2016 | clinicaltrials |
| NCT01384617 | Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy | completed | N/A | 136 | Wakayama Medical UniversityOTHER | 1 | Jul 21, 2016 | clinicaltrials |
| NCT01204476 | Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2016 | clinicaltrials |
| NCT00049023 | Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors | completed | Phase 1 | 27 | O'Dorisio, M SOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT00416767 | Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Federation Francophone de Cancerologie DigestiveOTHER | 0 | May 30, 2016 | clinicaltrials |
| NCT01658436 | BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. | completed | Phase 2 | 31 | Novartis PharmaceuticalsINDUSTRY | 9 | May 2, 2016 | clinicaltrials |
| NCT01317615 | RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation | completed | Phase 4 | 49 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 30, 2016 | clinicaltrials |
| NCT01099540 | Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor | completed | Phase 2 | 37 | Samsung Medical CenterOTHER | 1 | Dec 29, 2015 | clinicaltrials |
| NCT00610129 | Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) | completed | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT01135849 | B-Receptor Signaling in Cardiomyopathy | completed | — | 99 | Daniel BernsteinOTHER | 1 | Nov 17, 2015 | clinicaltrials |
| NCT01548482 | Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2015 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT02539433 | Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA) | completed | N/A | 22 | Northwell HealthOTHER | 1 | Sep 3, 2015 | clinicaltrials |
| NCT00978211 | DOTA-TOC in Metastasized Neuroendocrine Tumors | completed | Phase 2 | 1,499 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 7, 2015 | clinicaltrials |
| NCT02125929 | Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms | completed | N/A | 156 | Peking Union Medical College HospitalOTHER | 1 | Aug 6, 2015 | clinicaltrials |
| NCT00937079 | Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients | completed | — | 30 | University Hospital, Basel, SwitzerlandOTHER | 1 | Jan 9, 2015 | clinicaltrials |
| NCT01689064 | Comparison of Surgical Approach to Endoscopic Pituitary Adenoma Resection | completed | N/A | 55 | University of CalgaryOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT00412061 | Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor(RADIANT-2) | completed | Phase 3 | 429 | Novartis PharmaceuticalsINDUSTRY | 15 | Nov 21, 2014 | clinicaltrials |
| NCT00131911 | Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | completed | Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2014 | clinicaltrials |
| NCT01121562 | Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 12 | PfizerINDUSTRY | 1 | Jun 30, 2014 | clinicaltrials |
| NCT01465672 | Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis | completed | — | 125 | University Hospital, Basel, SwitzerlandOTHER | 1 | May 20, 2014 | clinicaltrials |
| NCT00942682 | Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | completed | Phase 1 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Oct 29, 2018source: clinicaltrials